Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Share News (SYNC)

Share Price Information for Syncona (SYNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 110.00
Bid: 110.00
Ask: 110.20
Change: 1.60 (1.48%)
Spread: 0.20 (0.182%)
Open: 107.40
High: 110.20
Low: 107.40
Prev. Close: 108.40
SYNC Live PriceLast checked at -
Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IN BRIEF: Syncona notes FDA acceptance of Autolus's BLA for obe-cel

Mon, 22nd Jan 2024 12:19

Syncona Ltd - London-based investor in healthcare companies - The US Food & Drug Administration accepts Autolus Therapeutics PLC's biologics licence application for obe-cel for patients with relapsed/refractory adult B-cell acute lymphoblastic leukaemia. The FDA has set a target action date of November 16 for reviewing the application, Syncona says. Further, Autolus is on track to submit a marketing authorisation application to the EU's European Medicines Agency in the first half of 2024.

Syncona has an 18% stake in Autolus.

Current stock price: 117.05 pence, down 0.3% on Monday

12-month change: down 31%

By Tom Budszus, Alliance News slot editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
3 Aug 2020 22:16

UK TRADING UPDATE SUMMARY: Bluebird To Buy Southern Gold Venture Stake

UK TRADING UPDATE SUMMARY: Bluebird To Buy Southern Gold Venture Stake

Read more
20 Jul 2020 08:44

Syncona Investee Freeline Therapeutics Files For Possible US Listing

Syncona Investee Freeline Therapeutics Files For Possible US Listing

Read more
20 Jul 2020 07:22

Syncona's Freeline files IPO registration document

(Sharecast News) - Healthcare investor Syncona said its portfolio company Freeline Therapeutics has filed a registration statement with the US Securities and Exchange Commission for a proposed initial public offering (IPO).

Read more
13 Jul 2020 18:36

Syncona's Investee Freeline Publishes Further Data For FLT180a

Syncona's Investee Freeline Publishes Further Data For FLT180a

Read more
30 Jun 2020 10:33

Syncona Investee Freeline Raises USD120 Million And Mulls US Listing

Syncona Investee Freeline Raises USD120 Million And Mulls US Listing

Read more
30 Jun 2020 08:26

Syncona revalues holding in Freeline after expanded series C

(Sharecast News) - Healthcare investment and development company Syncona announced on Tuesday that Freeline Therapeutics - a biotechnology company focussed on developing curative gene therapies for chronic systemic diseases - has raised a further $80m (£65.09m) from specialist global institutional investors in an expanded series C round.

Read more
18 Jun 2020 16:40

DIRECTOR DEALINGS: Syncona Non-Exec Reverberi Buys GBP50,000 In Shares

DIRECTOR DEALINGS: Syncona Non-Exec Reverberi Buys GBP50,000 In Shares

Read more
15 Jun 2020 09:19

Former Bayer Healthcare Chief Medical Officer Malik Joins Syncona

Former Bayer Healthcare Chief Medical Officer Malik Joins Syncona

Read more
11 Jun 2020 09:26

Syncona Annual Assets Take Hit From Autolus Value But Likes Portfolio

Syncona Annual Assets Take Hit From Autolus Value But Likes Portfolio

Read more
11 Jun 2020 08:32

Syncona asset values fall after Autolus shares plunge

(Sharecast News) - Syncona reported a 13% fall in net asset value as the value of its life sciences division dropped by a quarter in its most recent financial year.

Read more
4 Jun 2020 18:21

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
29 May 2020 09:07

Syncona Investee Achilles Therapeutics Starts Melanoma Therapy Trial

Syncona Investee Achilles Therapeutics Starts Melanoma Therapy Trial

Read more
29 May 2020 08:12

Syncona portfolio firm Achilles doses first patient in T cell therapy trial

(Sharecast News) - Syncona announced on Friday that its portfolio company, Achilles Therapeutics, has dosed the first patient in a phase 1 and 2 clinical study of its clonal neoantigen T cell (cNeT) therapy, in patients with recurrent or metastatic malignant melanoma.

Read more
23 Apr 2020 11:01

Syncona Makes USD51 Million Investment Into SwanBio Therapeutics

Syncona Makes USD51 Million Investment Into SwanBio Therapeutics

Read more
23 Apr 2020 08:54

Syncona announces expanded commitment to SwanBio

(Sharecast News) - Syncona announced a new $51m (?41.39m) commitment in an expanded $77m series A round of financing by SwanBio Therapeutics on Thursday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.